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Abstract
Background: To analyze differences in brain natriuretic peptide (BNP) levels depending on
mitral flow pattern (MFP) and to assess the effects of carvedilol on changes in MFP, left
ventricular function and exercise capacity.
Methods and results: The study population consisted of 73 patients with symptomatic heart
failure in NYHA classes II and III and LVEF < 40% without prior beta-blockade. In all
patients at baseline, before carvedilol, and then at 3 and 12 months after initiation of treatment,
the following parameters were assessed: HRs, serum BNP, echocardiographic parameters, and
exercise capacity with gas monitoring during cardiopulmonary stress test. Before carvedilol there
was a positive correlation between BNP and E/A (r = 0.17; p = 0.05). BNP was significantly
higher in patients with restrictive MFP (rMFP) as compared with nonrestrictive MFP (nrMFP)
(541.5 ± 206.7 vs. 412.6 ± 207.2; p = 0.009), and lower VO2peak in rMFP as compared with nrMFP
(12.5 ± 3.7 vs. 16.5 ± 4.7; p = 0.001). After initiation of carvedilol, the patients with rMFP had
reduced E/A (2.9 vs. 1.4; p = 0.003), and rMFP was changed to nrMFP in 60.8% of patients.
Respective BNP concentrations were 342.16 ± 284.31 vs. 326.40 ± 264.6; NS. In patients with
rMFP VO2peak , %N increased significantly from 42.4 ± 10.2 to 52.4 ± 14.4; p = 0.012.
Conclusions: In patients with systolic congestive heart failure, the presence of rMFP is
related to higher BNP levels and reduced VO2peak. Chronic treatment with carvedilol replaces
rMFP with nrMFP and improves exercise capacity in some patients. (Cardiol J 2008; 15: 329–337)
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Introduction
In recent decades, left ventricular diastolic
dysfunction has been increasingly frequently stu-
died [1–3]. So far, left ventricular remodelling has
been discussed from the viewpoint of systolic func-
tion. In recent years a number of reports have been
published focusing on the importance of diastolic
impairment in patients with dilated cardiomyo-
pathy [4–7]. Marked diastolic dysfunction in pa-
tients with systolic heart failure is an unfavourable
prognostic factor [8].
Experimental and clinical studies have demon-
strated that prolonged heart failure is associated
with altered left ventricular filling pattern (MFP,
mitral flow pattern) on pulsed-wave Doppler [9–12].
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In most patients with systolic congestive heart failu-
re (CHF), altered diastolic filling pattern ranges from
impaired relaxation to restrictive MFP (rMFP) [11].
Several studies in patients with idiopathic car-
diomyopathy and ischemic cardiomyopathy have
shown that restrictive filling pattern rather than
systolic function is a predictor of cardiovascular
events [4, 11, 13, 14].
The assessment of left ventricular filling pat-
tern provides important prognostic information in
patients with systolic dysfunction, and according to
some investigators it may be a useful tool for mo-
nitoring the tolerance and effectiveness of pharma-
cological treatment [7, 14, 15]. A change from re-
strictive to non-restrictive filling pattern adds im-
portant prognostic information [16]. Xie et al. [4]
documented a close relationship between restric-
tive filling pattern and the functional status of the
patient, confirming that the parameter is a non-in-
vasive indicator of heart failure severity. Another
study showed that restrictive filling pattern, and
especially short deceleration time (DT < 140 ms),
is an indicator of left ventricular dysfunction that is
independent of left ventricular dimensions and ejec-
tion fraction, and is associated with reduced exer-
cise capacity on spiroergometry [5].
Mitral flow profile then adds valuable hemody-
namic and prognostic information in patients with
systolic dysfunction [7, 17].
Clinical studies reporting the efficacy of beta-
adrenergic blocking agents in patients with impa-
ired diastolic function are scarce and mainly con-
cern patients with preserved systolic function [18].
Capomolla et al. [19] evaluated the effects of carve-
dilol on diastolic function and mitral regurgitation
in patients with ischemic heart failure and idiopa-
thic cardiomyopathy. They demonstrated that chro-
nic treatment with carvedilol in patients with CHF
inhibits progression and dilatation of the left ven-
tricle and results in partial regression of filling ab-
normalities.
Reports on the effects of chronic beta-adrener-
gic blockade on diastolic function in patients with
systolic heart failure, and the outcomes based on
MFP and associated neurohormonal changes, espe-
cially BNP levels, are scarce [20].
The purpose of the present study was to:
— analyze differences in brain natriuretic pepti-
de (BNP) levels depending on mitral flow pat-
terns in patients with symptomatic systolic
heart failure;
— assess the effects of 12-month treatment with
carvedilol on changes in mitral flow pattern, left
ventricular function and exercise capacity.
Methods
The study population consisted of 73 patients
(68 men and 5 women) aged from 30 to 69 years
(54.8 ± 7.19) with symptomatic chronic heart failure
due to ischemic heart disease (58 patients) and idio-
pathic cardiomyopathy (15 patients). The patients re-
ceived treatment in the Department of Coronary
Heart Disease and Out-patient Cardiac Department
Institute of Cardiology CMUJ in Cracow in 2000–2004.
Patients with left ventricular ejection fraction
(LVEF) < 40% on echocardiography were recru-
ited. Exclusion criteria were as follows: fixed atrial
fibrillation, unstable angina pectoris, myocardial in-
farction, stroke, percutaneous transluminal corona-
ry artery (PTCA) or coronary artery bypass grafting
(CABG) within the previous 3 months, contraindi-
cations to beta-blockade, significant aortic or mitral
valve defects except functional mitral regurgitation
related to heart failure, renal failure and uncontrol-
led diabetes mellitus. Prior to inclusion 12 patients
(16%) had undergone PTCA within one coronary
artery, 6 patients (8%) CABG, 3 patients (4%) re-
ceived a DDD pacemaker, and one patient an im-
plantable cardioverter-defibrillator.
For at least 3 months prior to the study the pa-
tients had been receiving angiotensin converting
enzyme (ACE) inhibitors, diuretics and/or digoxin but
not beta-blockers. Of these patients, 25 (34%) were
in NYHA class II and 48 (66%) in NYHA class III.
Arterial hypertension World Health Organization sta-
ge III was diagnosed in 68.4% and diabetes mellitus
type 2 in 17.4%. Coronary angiography, performed in
70 patients, revealed significant lesions in 80%.
The study protocol was approved by the Local
Ethics Committee. All patients gave their informed
consent.
All patients at baseline, before carvedilol, and
then at 3 and 12 months after initiation of treatment,
underwent a panel of studies including assessment
of functional capacity according to NYHA. BNP le-
vels, echocardiograms and cardiopulmonary stress
test (CPX) parameters were obtained at baseline
and at 3 and 12 months.
Blood for measurements of BNP after overni-
ght fasting and 30 min rest in the morning was col-
lected from the antecubital vein in EDTA (Sarsted,
Germany) and centrifuged and the plasma was sto-
red at –30oC. Measurements were done in the La-
boratory of Radioligands in Cracow (head: Prof.
Marek Stępniewski). BNP was measured using an
immunoenzymatic method and reagents provided
by Immuno Biological Laboratories (Hamburg, Ger-
many) (normal values up to 100 pg/mL).
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The degree of beta-blockade was identified
from heart rate in ECG at rest (HRs).
Echocardiograms according to the Clinical
Echocardiographic Guidelines of the Polish Cardiac
Society [21] were obtained to measure cavity sizes,
ejection fraction, segmental wall motion abnormali-
ties and mitral flow parameters. M-mode echocar-
diography in parasternal long-axis projection was
performed to measure left ventricular end-systolic
dimensions (LVESd). 2D echocardiography was per-
formed to calculate left ventricular end-diastolic and
end-systolic volume (LVEDV, LVESV) adjusted for
body surface. Left ventricular ejection fraction was
calculated using the modified Simpson’s method,
averaging three consecutive measurements [22].
The size of the left atrium and right ventricle was
measured and the presence of regurgitation was
checked. Right ventricular pressure was calculated
from tricuspid regurgitation fraction.
Contractility was measured in each segment
separately using the wall motion score index
(WMSI) [23].
To find out associated left ventricular diastolic
dysfunction, routine mitral flow parameters were
assessed. E wave, A wave, E/A ratio, DT and iso-
volumetric relaxation time (IVRT) were measured
in patients with sinus rhythm in 4-chamber projec-
tion using the spectral pulsed wave Doppler tech-
nique with the sampling volume placed on the tips
of mitral leaflets [24]. In patients with normal mi-
tral flow pattern the retrograde pulmonary venous
blood flow was also analyzed [22]. Echocardiogra-
phy was performed using an Acuson Aspen device
with 4 MHz probe and simultaneous VHS recording.
Based on Doppler mitral flow parameters [25]
the following subgroups were identified:
— rMFP group — with restrictive mitral flow pat-
tern (23 patients), if E/A was > 2 or between
1 and 2, but DT was < 140 ms;
— nrMFP group — with nonrestrictive mitral flow
pattern (50 patients), if E/A was < 1 or betwe-
en 1 and 2, but DT was > 140 ms.
Exercise capacity and gas exchange parame-
ters were identified from a spiroergometric test
(CPX) on a treadmill using the modified Naughton’s
protocol. The test was conducted in patients who
were clinically stable for at least 2 weeks and on
current pharmacological regime. Before CPX, spi-
rometry at rest was performed. Maximal oxygen
consumption (VO2peak) was measured when the amo-
unt of oxygen used did not increase despite higher
workload. In patients who terminated the test be-
fore the plateau due to increasing dyspnea or fati-
gue, VO2peak was averaged from the values measu-
red in the last 30 s of the test and expressed as va-
lues adjusted for body mass (ml/kg/min) and as
a percentage of the normal value [26–28].
The following exercise stress test parameters
were analyzed: heart rate at rest (HRs), exercise
time (tmax) and workload (WAT). At peak exercise
the following parameters were identified: heart rate
(HRm), peak oxygen consumption expressed as kg/min
(VO2peak), and percentage of the normal value
(VO2peak%N), ventilatory equivalent for oxygen
(VE/VO2), ventilatory equivalent for carbon dioxide
(VE/VCO2), partial oxygen pressure (PETO2),
and partial carbon dioxide pressure in exhaled air
(PETCO2). In some patients, it was impossible to
define the anaerobic threshold.
At 3 and 12 months, changes in dosage of CHF
agents, heart transplantation and death were recorded.
Statistical analysis
Statistical analyses were made using the
STATISTICA package. Changes in the variable be-
tween measurements in the whole group, taking
into account a factor dividing the population into
subgroups, were analyzed using ANOVA with re-
peated measurements and Scheffe’s test. Relation-
ships between the two variables in the subgroups
were studied using Pearson’s linear correlation (r)
or Spearman’s (rs) correlation. A p value of 0.05 was
considered statistically significant.
Results
Clinical characteristics are summarized in
Table 1. Mitral flow was analyzed in 73 patients at
baseline. Nonrestrictive mitral flow pattern
(nrMFP) was found in 50 (68.5%) patients, and re-
strictive MFP (rMFP) in 23 (31.5%) patients. Mean
enalapril doses in both groups at baseline were 14.9 ±
± 7.3 mg/daily, mean diuretic dose (furosemide)
was 39.1 ± 19.2 mg/daily, and mean carvedilol at
3 months was 25.0 ± 13.5 mg/daily. The dosage did
not change significantly at 12 months.
At 3 months rMFP was seen less frequently
(19.2%) and at 12 months only in 14% of patients
(Table 2).
At 12 months rMFP changed to nrMFP in
14 patients (60.8%), whereas in 5 patients (21%) ba-
seline rMFP remained unchanged. Among patients
with nrMFP at baseline, rMFP was found only in
6 patients (12%). There was a positive correlation
between HRs and E/A (r = 0.55; p = 0.049).
Before initiation of carvedilol, patients in the
rMFP group were in a significantly worse NYHA
class, had significantly higher HRs, higher BNP
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levels, larger LVESd and LVEDd, lower LVEF, lar-
ger left atrium and higher left ventricular mass in-
dex, as compared with nrMFP patients. Table 3
summarizes the differences in clinical parameters
at baseline and after treatment, in both groups.
In rMFP patients, as early as at 3 months after
beta-blockade, E/A was significantly reduced (Fig. 1),
similar to WMSI from 2.4 ± 0.3 vs. 2.3 ± 0.3, p =
= 0.03, as compared with nrMFP patients. The re-
maining echocardiographic parameters remained
unchanged at 3 months after carvedilol. BNP levels
were found to be strongly associated with left ven-
tricular diastolic function. There was a positive cor-
relation between BNP and E/A (r = 0.17; p = 0.05)
Table 1. Clinical characteristics of patients before carvedilol treatment.
Heart failure etiology Idiopathic cardiomyopathy 15 (21%)
Ischemic cardiomyopathy 58 (79%)
Hypertension III degree acc. to WHO classification 50 (68,4%)
Hypercholesterolemia 53 (73%)
Previous myocardial infarction With Q wave 45 (52.3%)
Without Q wave 11 (12.8%)
NYHA functional class II 25 (34.9%)
III 48 (66%)
Mitral flow pattern Restrictive 23 (31.5%)
Nonrestrictive 50 (68.5%)
Coronary angiography (n = 70) Normal coronary arteries 14 (20%)
1-vessel disease 11 (19.6%)
2-vessel disease 15 (26.9%)
Multivessel disease 30 (53.4%)
Table 3. Selected parameters in rMFP and nrMFP groups assessed before beta-blockade and at
12 months after initiation of carvedilol therapy.
Before beta-blockade p At 12 months p
rMFP (c ±SD) nrMFP (c ±SD) rMFP (c ±SD) nrMFP (c ±SD)
NYHA class 2.86±0.36 2.5±0.52 0.001 1.6 ±0.6 1.8±0.5 NS
BNP [pg/ml] 541.5±206.7 412.6±207.2 0.009 342.16 ±284.3      326.40±264.6 NS
HRs [l/min] 91.3±17.31 83.4±17.4 0.043 69.7 ±9.1 68.6±13.2 NS
LVEF (%) 26.6±5.8 30.0±6.2 0.010 35.0 ±9.0 37.8±8.3 NS
LVESd [mm] 60.1±8.8 54.7±9.1 0.008 55.8 ±11.7 53.0±8.8 NS
LVEDd [mm] 70.8±7.0 67.7±7.3 0.050 66.7 ±9.3 65.6±8.5 NS
LA [mm] 48.1±6.6 43.0±6.1 0.001 45.4 ±6.3 40.9±5.1 0.001
WMSI 2.4±0.3 2.3±0.4 0.030 2.2 ±0.3 2.2±0.2 NS
E/A 2.9±1.2 1.0±0.4 0.001 1.4 ±0.9 1.2±0.7 NS
DT [ms] 185.8±89.04 265.8±75.96 0.001 196.9 ±76.7 249.9±100.8 0.03
IVRT 108.54±30.36 117.5±18.14 NS 110.7 ±31.9 94.6±26.5 NS
rMFP — restrictive mitral flow pattern; nrMFP — nonrestrictive mitral flow pattern; NYHA — New York Heart Association; BNP — brain natriuretic peptide;
HRs — heart rate at rest; LVEF — left ventricular ejection fraction; LVESd — left ventricular end-systolic diameter; LVEDd — left ventricular end-diastolic
diameter; LA — left atrium; WMSI — wall motion score index; E/A — E/A ratio; DT — deceleration time; IVRT — isovolumetric relaxation time
––––
Table 2. Changes in the occurrence of restrictive (rMFP) and nonrestrictive mitral flow pattern (nrMFP)
during therapy.
Mitral flow pattern Before beta-blockade At 3 months At 12 months
rMFP 23 (31.5%) 14 (19.2%) 10 (14.0%)
nrMFP 50 (68.5%) 59 (80.8%) 61 (86.0%)
All 73 73 71
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and a negative correlation between BNP and IVRT
(r = –0.19; p =  0.06). This may indicate that BNP
levels are related to the severity of left ventricular
diastolic impairment.
In rMFP patients at baseline, exercise time was
shorter, and workload and VO2peak were lower as
compared with nrMFP patients, implying a negati-
ve effect of restrictive mitral flow on exercise ca-
pacity in patients with failing hearts.
In patients with initial rMFP, 3-month beta-
-adrenergic blockade resulted in prolonged exerci-
se time from 480.9 s to 610.5 s, and at 12 months to
660.3 s; workload and metabolic equivalent were
also increased (Table 4). At 12 months, in rMFP
patients, VO2peak increased by a mean of 1.95 ml/kg/
/min. In nrMFP patients, VO2peak increased only by
0.23 ml/kg/min. VO2peak%N increased significantly
in rMFP patients from 42.4 ± 10.2 to 52.4 ± 14.4;
p = 0.012 (Table 5). In nrMFP patients both
VO2peak and VO2 peak%N remained unchanged during
treatment (Fig. 2). These findings indicate that the
change in mitral flow profile from restrictive to non-
Figure 1. Changes in E/A ratio values during carvedilol
therapy in patients with nonrestrictive (nrMFP) and re-
strictive (rMFP) mitral flow pattern.
Table 4. Correlations between BNP and E/A,
IVRT, LA, IM, RVSP before beta-blockade and
at 3 and 12 months after carvedilol therapy
BNP [pg/mL] — correlation values
at study time points
Before beta- At 3 months At 12 months
-blockade
E/A r = 0.17 r = 0.29 r = 0.16
p = 0.05  p = 0.005  NS
IVRT r = –0.19 r = –0.32 r = –0.22
p = 0.06  p = 0.002  p = 0.038
LA r = 0.20 r = 0.32 r = 0.12
p = 0.05 p = 0.002  NS
IM r= 0.20 r = 0.35 r = 0.21
p= 0.04  p = 0.001  p = 0.042
RVSP r = 0.24 r = 0.23 r = 0.29
p = 0.02  p = 0.032  p = 0.005
BNP — brain natriuretic peptide; E/A — E/A ratio; IVRT — isovolumetric
relaxation time; LA — left atrium; IM — mitral insufficiency;
RVSP — right ventricle systolic pressure
Table 5. Selected cardiopulmonary stress test parameters in rMFP and rnMFP groups before beta-
-blockade and at 12 months after initiation of carvedilol therapy.
Before beta-blockade p At 12 months p
rMFP (c ±SD) nrMFP (c ±SD) rMFP (c ±SD) nrMFP (c ±SD)
Tmax [l/min] 480.9±207.1 657.2±291.8 0.004 660.3±235.3 792.7±298.4 NS
WAT 54.3±29.0 80.3±47.9 0.004 85.4±39.3 107.6±41.5 NS
VO2peak [ml/kg/min] 12.5±3.7 16.5±4.7 0.001 14.5±3.1 16.7±4.6 NS
VO2peak [%N] 42.4±10.2 58.0±15.5 0.041 52.4±14.4 59.0±15.6 NS
VE/VCO2 37.86±9.45 36.7±7.41 37.6±7.8 38.9±8.57
Tmax — stress test duration time; VO2peak, — peak oxygen consumption; WAT — workload; VO2peak%N — percentage of the normal value; VE/VCO2 —
ventilatory equivalent for oxygen
– – – –
Figure 2. Comparison of peak oxygen consumption
(VO2peak%) changes in rMFP and nrMFP groups asses-
sed before beta blockade and after 3 and 12 months
carvedilol therapy.
334
Cardiology Journal 2008, Vol. 15, No. 4
www.cardiologyjournal.org
restrictive improves exercise capacity in heart
failure patients. When the frequency of restrictive
mitral flow profile was analyzed in association with
peak oxygen consumption, rMFP was seen in 64%
of patients with VO2peak < 14 ml/kg/min at baseline,
as compared with 14.8% of patients with VO2peak >
> 14 ml/kg/min. At 12 months the number of pa-
tients with VO2peak < 14 ml/kg/min decreased from
25 to 13, and rMFP was found in 33% of them.
At one year of follow-up there were 3 deaths,
whereas at follow-up of 5 to 36 months, mean 22.81 ±
± 6.46 months, there were 5 deaths. At 3 mon-
ths these patients had lower LVEF as compared
with the survivors (28.3 ± 2.6 vs. 34.4 ± 7.6;
p = 0.029) and higher E/A (2.7 ± 0.8 vs. 1.4 ±
± 0.9; p = 0.003) corresponding with restrictive
mitral flow pattern. Moreover, those who died had
a larger left atrium (48.7 ± 6.6 vs. 42.3 ± 3.1;
p = 0.003) and higher WMSI (2.5 ± 0.1 vs. 2.2 ±
± 0.3; p = 0.049).
Discussion
In CHF patients, the efficacy of pharmacologi-
cal treatment is usually evaluated from left ventri-
cular systolic function as the most reliable indica-
tor of left ventricular impairment. Left ventricular
systolic dysfunction in heart failure is usually asso-
ciated with diastolic dysfunction. Diastolic impair-
ment in patients with LVEF < 45% is an additional
factor of poor prognosis. Evidence shows that re-
strictive mitral flow pattern is the strongest indica-
tor of poor prognosis in patients after myocardial
infarction and with dilated cardiomyopathy [11, 29].
In patients with left ventricular systolic dys-
function in the course of various diseases, diastolic
function is also impaired, which is associated with
relaxation abnormalities, decreased compliance and
disordered left ventricular geometry because of
ventricular dilatation [12]. In some patients with
dilated cardiomyopathy, mitral flow pattern is typi-
cal of impaired relaxation, and in others restrictive
MFP is associated with increased filling and mar-
ked left ventricular stiffness [5, 6, 30–35].
In the present study, rMFP was found in 30%
of patients at baseline, nrMFP (impaired relaxation
or pseudonormalization) in 65%, and only 5% had
normal mitral flow pattern.
There was a relationship between the presen-
ce of restriction and NYHA class. The correlation
between NYHA class and E/A confirmed the depen-
dence between circulatory capacity and diastolic
dysfunction. According to some investigators, CHF
patients with rMFP have more severe clinical symp-
toms of heart failure, more frequent third heart so-
und, increased left ventricular end-diastolic pres-
sure, more severe ventricular dilatation, larger left
atrium, higher wedge pressure and mitral regurgi-
tation [36]. For this reason, restrictive mitral flow
pattern may be a marker of hemodynamic abnorma-
lities and usually implies increased left ventricular
end-diastolic pressure and pulmonary wedge pres-
sure [37].
In the present study, carvedilol induced signifi-
cant changes in systolic and diastolic ventricular func-
tion corresponding with positive left ventricular re-
modelling. The significantly reduced HRs at 3 mon-
ths, as a manifestation of beta-blockade, was partly
associated with insignificant improvement of left ven-
tricular systolic function (increased LVEF, decreased
LVEDd) and significant improvement of wall motion.
In patients with rMFP, the significantly reduced HRs
at 3 months also resulted in E/A reduction and DT
prolongation, i.e. diastolic improvement. At 12 mon-
ths, diastolic function remained unchanged.
The present study shows that the most affec-
ted patients, i.e. the patients with restricted mitral
flow pattern, showed improved diastolic function at
3 months. It was the first, favourable manifestation
of carvedilol efficacy.
The lack of significant difference in LVEF be-
tween patients with restrictive and nonrestrictive
MFP after 12-months carvedilol therapy may indi-
cate that systolic improvement, to a considerable
degree, depends on the reversibility of initial dia-
stolic dysfunction.
The present findings are concordant with the
results of Andersson et al. [38], who found that dia-
stolic function was most markedly improved at
3 months after metoprolol, whereas LVEF incre-
ased significantly at 6 and 12 months.
Changes in left ventricular diastolic function
are related to a number of factors including relaxa-
tion velocity, left ventricular wall stiffness and pres-
sure gradient between the left ventricle and left
atrium. Active myocardial relaxation is responsible
for left ventricular pressure reduction and rapid fil-
ling after mitral valve opening. Relaxation affects
isovolumetric diastole, early filling in mitral flow,
and E/A. Deceleration time is significantly related
to left ventricular wall stiffness [22].
Despite various limitations associated with the
assessment of left ventricular diastolic function
based on traditional parameters (E/A, DT, IVRT) re-
lated to age and heart rate, evidence shows the pro-
gnostic value of diastolic dysfunction and its corre-
lation with heart failure progression [25]. In the
present study the mean age was 56.0 ± 9.19 years,
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and none of the patients was over 70. Of the left ven-
tricular diastolic parameters studied, mainly E/A was
found to be affected by beta-adrenergic blockade.
The recent SWEDIC study (Results of the
Swedish Doppler-Echocardiographic Study) was
designed to investigate the effect of carvedilol on
diastolic function (E/A, DT, IVRT) in patients with
heart failure and preserved systolic function. Carve-
dilol was found to significantly change E/A. The E/A
ratio is considered the most useful indicator of dia-
stolic dysfunction in CHF patients. The study sho-
wed that the beneficial effects of carvedilol, as com-
pared with placebo, included a significantly impro-
ved E/A, which was found in patients with initial
heart rate > 71 bpm [18]. The investigators conc-
luded that the benefits of carvedilol resulted from
improved early filling of the left ventricle [18].
In the present study, rMFP patients were in
worse NYHA class, had larger left atrium, mitral re-
gurgitation, and lower exercise capacity on CPX and
VO2peak as compared with nrMFP patients. Carvedilol
for 12 months in rMFP patients reduced left atrial
size and mitral regurgitation. This finding is indi-
rect proof that improved diastolic function after
beta-adrenergic blockade significantly affects left
atrial function, which is concordant with the recent
study on left atrial size and left ventricular diasto-
lic function [39].
In heart failure, we observe an early rise in BNP
[40, 41]. Its excessive release in CHF patients is an
important element of neurohumoral activation. BNP
concentrations increase in proportion to the severity
of heart failure. For this reason, BNP may add pro-
gnostic information to identify patients at risk [42, 43].
In the present study, BNP was markedly ele-
vated at baseline in rMFP patients as compared with
nrMFP patients. The correlation between BNP and
diastolic function parameters indicates a relation-
ship between diastolic dysfunction and elevated
BNP. Higher BNP at baseline was associated with
larger left atrium, mitral regurgitation, right ventri-
cular size and elevated pulmonary arterial pressure.
Recently it has been reported that severe diastolic
impairment or high-grade mitral regurgitation may
induce excessive BNP secretion also by atrial my-
ocytes [44].
So far, most reports have dealt with BNP in
patients with left ventricular diastolic dysfunction
and normal systolic function [45]. In 2004 Tough-
ton et al. [44] demonstrated increased BNP in pa-
tients with diastolic heart failure and left ventricu-
lar systolic dysfunction.
In the present study, 12-month treatment with
carvedilol was associated with a significant decrease
in BNP, especially in patients with rMFP at baseli-
ne. At 12 months, BNP levels were similar in patients
with rMFP and nrMFP. This finding, and the asso-
ciated improvement in diastolic function in rMFP
patients, indicates that changes in BNP correspond
with the degree of diastolic function improvement.
Exercise capacity in patients with heart failure
depends primarily on left ventricular diastolic func-
tion, which was confirmed in the present study.
Patients with rMFP had significantly lower
VO2peak in comparison to nrMFP patients. Restricti-
ve MFP was also more frequent among patients
with VO2peak < 14 ml/kg/min. Chronic treatment
with carvedilol was associated with a significant
improvement in diastolic function and an increase
in VO2peak by a mean of 1.95 ml/kg/min. These fin-
dings indicate a significant relationship between
diastolic improvement and peak oxygen consump-
tion in patients with restriction that is reversible
by beta-adrenergic blockade, and imply that the
subjects who benefit most from beta-adrenergic
blockade with carvedilol are those with the poorest
exercise capacity at baseline.
The mechanism of the positive effects of ca-
rvedilol on diastolic function is not clear. Short re-
laxation time is an unfavourable factor, especially
when myocardial function is impaired. Beta-adre-
nergic blockade prolongs diastole more than systo-
le, which in turn augments diastolic filling and im-
proves myocardial function and metabolism.
According to Bergstrom et al. [18], the benefi-
cial effects of carvedilol on diastolic function are as-
sociated with slowing down the left ventricular fil-
ling rate rather than augmenting myocardial rela-
xation. Ventricular filling is shifted from late to early
diastole, thus normalizing its course. Sequelae of
reduced heart rate are difficult to differentiate from
other effects of beta blockade. However, evidence
shows that beta-blockers do not only act through
reduction of heart rate. Other negative chronotro-
pic agents such as calcium channel blockers do not
produce similar outcomes in CHF patients [18].
Previous studies have shown that restrictive
mitral flow pattern is associated with increased
mortality rate in CHF patients [11, 30]. The pre-
sent study confirms this finding. Of the 5 patients
who died during follow-up, 3 had rMFP at baseline,
which remained unchanged despite treatment. The
remaining 2 patients had nrMFP before beta-bloc-
kade. After treatment, nrMFP changed to rMFP in
one patient, and nrMFP remained unchanged in one
patient. The annual mortality rate among patients
with restrictive MFP was 17% and was lower than
that reported by Pinamonti et al. [17], i.e. 35%.
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Evidence shows that rMFP which remains unchan-
ged during treatment is an independent progno-
stic factor [17].
The present study shows that preserved rMFP
or no changes after treatment may be an indicator
of poor prognosis.
Limitation of the study
The main limitation of the study is its inhomo-
geneous population for evaluation of the severity
of diastolic dysfunction and the influence of phar-
macotherapy. Because of the small sample size, we
used a simplified classification of diastolic dysfunc-
tion into restrictive and nonrestrictive mitral flow
pattern. The small sample size also prevented us
from evaluating changes in diastolic function with
respect to the severity of systolic impairment.
Conclusions
1. Restrictive mitral flow pattern in patients with
systolic heart failure is associated with higher
heart rate at rest, worse exercise capacity, lo-
wer peak oxygen consumption and higher bra-
in natriuretic peptide levels in comparison with
patients with nonrestrictive mitral flow pattern.
2. A change from restrictive to nonrestrictive
mitral flow pattern after treatment is the first
manifestation of positive carvedilol effects pre-
ceding systolic improvement.
Acknowledgements
The authors do not report any conflict of inte-
rest regarding this work.
References
1. Banerjee P, Banerjee T, Khand A, Clark AL, Cleland JG.
Diastolic heart failure: Neglected or misdiagnosed? J Am Coll
Cardiol, 2002; 39: 138–141.
2. Angeja BG, Grossman W. Evaluation and management of dias-
tolic heart failure. Circulation, 2003; 107: 659–663.
3. Brutsaert DL. Diagnosing primary diastolic heart failure.
Eur Heart J, 2000; 21: 94–96.
4. Xie GY, Berk MR, Smith MD, Gurley JC, DeMaria AN. Prognostic
value of Doppler transmitral flow patterns in patients with con-
gestive heart failure. J Am Coll Cardiol, 1994; 24: 132–139.
5. Tabet JY, Logeart D, Geyer C et al. Comparison of the prognos-
tic value of left ventricular filling and peak oxygen uptake in
patients with systolic heart failure. Eur Heart J, 2000; 21: 1864–
–1871.
6. Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic
and diastolic dysfunction in patients with clinical diagnosis of
dilated cardiomyopathy. Relation to symptoms and prognosis.
Circulation, 1994; 90: 2772–2779.
7. Capomolla S, Pinna GD, Febo O, Caporotondi A, Guazzotti G,
La Rovere MT. Echo-Doppler mitral flow monitoring: An opera-
tive tool to evaluate day-to-day tolerance to and effectiveness of
beta-adrenergic blocking agent therapy in patients with chronic
heart failure. J Am Coll Cardiol, 2001; 38: 1675–1684.
8. Torosoff M, Philbin EF. Improving outcomes in diastolic heart
failure. Techniques to evaluate underlying causes and target
therapy. Postgrad Med, 2003; 113: 51–58.
9. Ohno M, Cheng CP, Little WC. Mechanism of altered patterns
of left ventricular filling during the development of congestive
heart failure. Circulation, 1994; 89: 2241–2250.
10. Traversi E, Pozzoli M, Cioffi G et al. Mitral flow velocity changes
after 6 months of optimized therapy provide important hemody-
namic and prognostic information in patients with chronic heart
failure. Am Heart J, 1996; 132: 809–819.
11. Witkowska M. Zaburzenia czynności rozkurczowej serca:
Patofizjologia, diagnostyka, leczenie. Wydawnictwo Lekarskie
PZWL, Warszawa 2002.
12. Nessler J, Skrzypek A, Piwowarska W. Diastolic dysfunction as
a risk factor in patients with heart failure. Przegl Lek, 2004; 61:
962–967.
13. Palazzuoli A, Bruni F, Puccetti L et al. Effects of carvedilol on left
ventricular remodeling and systolic function in elderly patients
with heart failure. Eur J Heart Fail, 2002; 4: 765–770.
14. Giannuzzi P, Temporelli PL, Bosimini E et al. Independent and
incremental prognostic value of Doppler-derived mitral deceler-
ation time of early filling in both symptomatic and asymptomatic
patients with left ventricular ysfunction. J Am Coll Cardiol, 1996;
28: 383–390.
15. Pozzoli M, Traversi E, Cioffi G, Stenner R, Sanarico M, Tavazzi L.
Loading manipulations improve the prognostic value of Doppler
evaluation of mitral flow in patients with chronic heart failure.
Circulation, 1997; 95: 1222–1230.
16. Dhir M, Nagueh SF. Echocardiography and prognosis of heart
failure. Curr Opin Cardiol, 2002; 17: 253–256.
17. Pinamonti B, Zecchin M, Di Lenarda A, Gregori D, Sinagra G,
Camerini F. Persistence of restrictive left ventricular filling pat-
tern in dilated cardiomyopathy: an ominous prognostic sign.
J Am Coll Cardiol, 1997; 29: 604–612.
18. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H,
Dahlstrom U. Effect of carvedilol on diastolic function in pa-
tients with diastolic heart failure and preserved systolic func-
tion. Results of the Swedish Doppler-echocardiographic study
(SWEDIC). Eur Heart Failure, 2004; 453–461.
19. Capomolla S, Febo O, Gnemmi M et al. Beta-blockade thera-
py in chronic heart failure: diastolic function and mitral regur-
gitation improvement by carvedilol. Am Heart J, 2000; 139:
596–608.
20. Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van Lente F.
Plasma B-type natriuretic peptide levels in ambulatory patients
with established chronic symptomatic systolic heart failure. Cir-
culation, 2003; 108: 2964–2966.
21. Standardy Echokardiografii Klinicznej Sekcji Echokardiografii
Polskiego Towarzystwa Kardiologicznego (www.ptkardio.pl/
/standardy/haslo/start_n.html).
22. Kasprzak JD, Wierzbowska-Drabik K, Drożdż J. Ocena czynności
lewej komory — funkcja skurczowa i rozkurczowa. In: Podolec P,
Tracz W., Hoffman P eds. Echokardiografia praktyczna. Vol. I,
Medycyna Praktyczna, Kraków 2004: 135–147.
337
Jadwiga Nessler et al., Restrictive filling pattern in HF patients treated with carvedilol
www.cardiologyjournal.org
23. Szwed H. Diagnostyka echokardiograficzna niedokrwiennej
przebudowy serca. In: Szyszka A ed. Przebudowa serca.
Via Media, Gdańsk 2002: 31–48.
24. Nessler J, Hlawaty M. Projekcje w echokardiografii przezklat-
kowej. In: Podolec P, Tracz W., Hoffman P eds. Echokardiografia
praktyczna. Vol. I. Medycyna Praktyczna, Kraków 2004: 59–73.
25. Hansen A, Haass M, Zugck C et al. Prognostic value of Doppler
echocardiographic mitral inflow patterns: implications for risk
stratification in patients with chronic congestive heart failure.
J Am Coll Cardiol, 2001; 37: 1049–1055.
26. Podolec P, Tomkiewicz L, Szczęśniak J, Tracz W. The role of
cardiopulmonary exercise testing in cardiology. The description
of testing procedure and selected parameters needed for evalua-
tion of the cardiopulmonary system function. Przeg Lek, 1998;
55: 57–63.
27. Working Group on Cardiac Rehabilitation & Exercise Physiolo-
gy and Working Group on Heart Failure of the European Society
of Cardiology. Recommendations for exercise testing in chronic
heart failure patients. Eur Heart J, 2001; 22: 37–45.
28. Podolec P, Tomkiewicz-Pajak L, Pieculewicz M et al. Reproduc-
ibility of spiro-ergometric exercise test parameters in patients
with heart failure. Przegl Lek, 2002; 59: 580–582.
29. Yu HC, Sanderson JE. Different prognostic significance of right
and left ventricular diastolic dysfunction in heart failure. Clin
Cardiol, 1999; 22: 504–512.
30. Rihal CS, Nishimura RA, Hatle LK, Bailey KR, Tajik AJ. Systolic
and diastolic dysfunction in patients with clinical diagnosis of
dilated cardiomyopathy. Relation to symptoms and prognosis.
Circulation, 1994; 90: 2772–2779.
31. Spirto P, Maron BJ, Bonow RO. Noninvasive assessment of left
ventricular diastolic function: comparative analysis of Doppler
echocardiographic and radionuclide angiographic techniques.
J Am Coll Cardiol, 1986; 7: 518–526.
32. Stauffer J, Gaash WH. Recognition and treatment of left ventricular
diastolic dysfunction. Prog Cardiovasc Disc, 1990; 32: 319–332.
33. Vanoverschelde J-LJ, Raphael DA, Robert AR, Cosyns JR. Left
ventricular filling in dilated cardiomyopathy: Relation to func-
tional class and hemodynamics. J Am Coll Cardiol, 1990; 15:
1288–1295.
34. Vasan R, Benjamin EJ, Levy D. Congestive heart failure with
normal left ventricular systolic function. Arch Intern Med, 1996;
156: 146–157.
35. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features
and prognosis of diastolic heart failure: An epidemiologic per-
spective. J Am Coll Cardiol, 1995; 26: 1565–1574.
36. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients
with idiopathic or ischemic dilated cardiomyopathy assessed for
cardiac transplantation. Am J Cardiol, 1990; 65: 903–908.
37. Giannuzzi P, Temporelli PL, Bosimini E et al. Independent and
incremental prognostic value of Doppler-derived mitral deceler-
ation time of early filling in both symptomatic and asymptomatic
patients with left ventricular dysfunction. J Am Coll Cardiol,
1996; 28: 383–390.
38. Andersson B, Caidahl K, di Lenarda A et al. Changes in early and
late diastolic filling patterns induced by long-term adrenergic
beta-blockade in patients with idiopathic dilated cardiomyopa-
thy. Circulation, 1996; 94: 673–682.
39. Moller JE, Hillis GS, Oh JK. Left atrial volume: A powerful pre-
dictor of survival after acute myocardial infarction. Circulation,
2003; 107: 2207–2212.
40. Gackowski A, Isnard R, Piwowarska W, Komajda M. B-type
natriuretic peptide. New tool in clinical cardiology. Kardiol Pol,
2002; 56: 644–648.
41. Cheung BM, Kumana CR. Natriuretic peptides — relevance in
cardiovascular disease. JAMA, 1998; 280: 1983–1984.
42. Cowie MR. BNP: Soon to become a routine measure in the care
of patients with heart failure? Heart, 2000; 83: 617–618.
43. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P,
von Scheidt W. Role of brain natriuretic peptide in risk stratifi-
cation of patients with congestive heart failure. J Am Coll Cardiol,
2001; 38: 1934–1941.
44. Troughton RW, Prior DL, Pereira JJ et al. Plasma B-type natriu-
retic peptide levels in systolic heart failure: importance of left
ventricular diastolic function and right ventricular systolic func-
tion. J Am Coll Cardiol, 2004; 43: 416–422.
45. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriu-
retic peptide in detecting diastolic dysfunction: Comparison with
Doppler velocity recordings. Circulation, 2002; 105: 595–601.
